We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals
Read MoreHide Full Article
IQVIA Holdings Inc. (IQV - Free Report) today announced that it has collaborated with NRx Pharmaceuticals (NRXP - Free Report) for pharmacovigilance services and medical information.
NRx Pharmaceuticals is a clinical-stage small-molecule pharmaceutical company involved in the development of therapeutics for the treatment of pulmonary diseases and central nervous system disorders. The company's product, ZYESAMI, is an investigational pre-commercial drug for COVID-19-associated respiratory failure and is currently under phase III trials.
As part of the tie-up, IQVIA and NRx will work closely to support activities essential for emergency use authorization of ZYESAMI, including pharmacovigilance and medical information programs. To do so, IQVIA will give NRx access to its domain experience with Covid-19, required data assets and analytics.
"We are honored by the opportunity to join with NRx on the EUA activation and compliance for ZYESAMI in treating some of the sickest patients suffering from COVID-19," said Susan Kitlas, vice president, Precommercial Business Unit, IQVIA.
IQVIA’s shares have gained 55.1% over the past year against 26.5% decline of the industry it belongs to. The Zacks S&P 500 composite rose 32.6% in the said time frame.
Image: Bigstock
IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals
IQVIA Holdings Inc. (IQV - Free Report) today announced that it has collaborated with NRx Pharmaceuticals (NRXP - Free Report) for pharmacovigilance services and medical information.
NRx Pharmaceuticals is a clinical-stage small-molecule pharmaceutical company involved in the development of therapeutics for the treatment of pulmonary diseases and central nervous system disorders. The company's product, ZYESAMI, is an investigational pre-commercial drug for COVID-19-associated respiratory failure and is currently under phase III trials.
As part of the tie-up, IQVIA and NRx will work closely to support activities essential for emergency use authorization of ZYESAMI, including pharmacovigilance and medical information programs. To do so, IQVIA will give NRx access to its domain experience with Covid-19, required data assets and analytics.
"We are honored by the opportunity to join with NRx on the EUA activation and compliance for ZYESAMI in treating some of the sickest patients suffering from COVID-19," said Susan Kitlas, vice president, Precommercial Business Unit, IQVIA.
IQVIA’s shares have gained 55.1% over the past year against 26.5% decline of the industry it belongs to. The Zacks S&P 500 composite rose 32.6% in the said time frame.
IQVIA Holdings Inc. Price
IQVIA Holdings Inc. price | IQVIA Holdings Inc. Quote
Zacks Rank and Stocks to Consider
IQVIA currently carries a Zacks Rank #3 (Hold).
Some other top-ranked stocks in the broader Zacks Business Services sector are Equifax (EFX - Free Report) and Genpact (G - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The long-term expected earnings per share (three to five years) growth rate for Equifax and Genpact is pegged at 15.2% and 14.7%, respectively.